Business Context and Reporting Period
Lisata Therapeutics, Inc. (Lisata) is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational drug designed to enhance the delivery of anti-cancer therapies to solid tumors via the CendR active transport mechanism. The filing is an Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
As of the filing date (March 12, 2026), the Company has entered into a definitive agreement to be acquired by Kuva Labs, Inc., which, if consummated, will result in the delisting of Lisata from the Nasdaq Capital Market.
Key Financial Metrics
| Metric (in thousands) | Year Ended Dec 31, 2025 | Year Ended Dec 31, 2024 |
|---|---|---|
| Revenue | $170 | $1,000 |
| Net Loss | $(16,586) | $(19,985) |
| Operating Expenses | $18,379 | $23,409 |
| Cash and Cash Equivalents (Dec 31, 2025) | $15,956 | $16,209 |
| Working Capital | $14,632 | $28,965 |
| Stockholders' Equity | $14,855 | $29,571 |
Liquidity: The Company reported a net cash outflow from operating activities of $15.9 million in 2025. Management has concluded there is substantial doubt regarding the Company's ability to continue as a going concern for twelve months following the issuance of the financial statements without additional financing.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 83% to $0.17 million in 2025 from $1.0 million in 2024. The 2024 revenue included a $1.0 million upfront payment from a collaboration with Kuva Labs (which was later terminated due to default), whereas 2025 revenue consisted of minor license fees.
- Expense Reduction: Total operating expenses decreased by 21.5% to $18.4 million.
- R&D Expenses: Decreased 30% to $7.9 million, driven by reduced spending on the ASCEND trial, lower patient treatment costs, and elimination of clinical department positions.
- G&A Expenses: Decreased 13.6% to $10.4 million, primarily due to a reversal of bonus accruals and lower consulting spend.
- Net Loss Improvement: Net loss narrowed by approximately $3.4 million to $16.6 million, reflecting the reduction in operating expenses.
- Investment Portfolio: Marketable securities were fully liquidated or reclassified; the balance sheet shows $0 in marketable securities for 2025 compared to $15.0 million in 2024.
Guidance, Outlook, and Material Events
Proposed Acquisition by Kuva Labs
On March 6, 2026, Lisata entered into a Merger Agreement with Kuva Labs. The offer price is $5.00 per share in cash plus one non-tradeable Contingent Value Right (CVR) representing a potential $1.00 per share if an NDA for certepetide is filed within seven years of closing. The transaction is expected to close in Q2 2026, subject to customary conditions.
Clinical Development Updates
- ASCEND Trial (mPDAC): Preliminary data from Cohort B (two doses of certepetide) showed clinically meaningful improvements in Progression-Free Survival (PFS) and Objective Response Rate (ORR) compared to placebo. Final study reports are anticipated in 2026.
- BOLSTER Trial (Cholangiocarcinoma): Completed; demonstrated no evidence of benefit or increase in adverse events with a single dose of certepetide.
- Qilu Termination: The exclusive license agreement with Qilu Pharmaceutical for the Greater China territory was mutually terminated on January 23, 2026, reverting all rights to Lisata.
Risks and Contingencies
- Going Concern: The Company has a history of losses and negative cash flows. Continued operations depend on raising additional capital or consummating the Kuva acquisition.
- Transaction Risk: The proposed acquisition is subject to conditions beyond the Company's control. Failure to close could materially adversely affect the business and stock price.
- Regulatory: No products are currently approved for commercial sale. Future revenue depends on regulatory approval of certepetide.
Investor Verification Checklist
- Acquisition Status: Verify the progress of the Kuva Labs tender offer and the likelihood of closing conditions being met.
- Cash Runway: Confirm the Company's current cash burn rate and the sufficiency of the $16.0 million cash balance to fund operations until the acquisition closes or new financing is secured.
- Clinical Data: Review the final data readout from the ASCEND trial (Cohort B) to assess the probability of regulatory approval for certepetide.
- Qilu Termination Impact: Assess the strategic implications of regaining full rights to the Greater China territory and the loss of potential milestone payments from Qilu.
- Going Concern Opinion: Review the auditor's report regarding the substantial doubt on the Company's ability to continue as a going concern.